Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Rising public awareness about myelodysplastic syndromes (MDS) and its early diagnosis and availability of new treatment options for MDS are expected to drive growth of the market over the forecast period. Moreover, early diagnosis of MDS is important because it significantly increases the quality of life in patients by early treatment, it also reduces the chances of recurrent blood transfusion and in more severe cases, as in 30% of the time, it can prohibit the evolution of the MDS disease into leukemia. Government organizations and drug manufacturing companies are focusing on spreading awareness about MDS by providing funding and conducting awareness programs. For instance, in October 2018, Grupo Biotoscana, a Latin American (Headquartered in Montevideo, Uruguay and with presence in 10 countries throughout the region) biopharmaceutical company conducted campaign to honor Myelodysplastic Syndrome World Awareness Day, which is celebrated on October 25. GBT Grupo Biotoscana launched a campaign to raise awareness and educate about disease throughout the October month.   

The U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market is estimated to be valued at US$ 2,042.6 Mn in 2020 and is expected to reach US$ 3,404.1 Mn by 2027, exhibiting a CAGR of 7.6% over the forecast period (2020-2027).

Figure 1. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market Value (US$ Mn), and Y-o-Y Growth (%), 2016-2027

U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment  | Coherent Market Insights

The growing effort to introduce highly effective therapies for various MDS types is expected to drive the market growth over the forecast period.  

The rising efforts made by pharmaceutical companies to introduce highly effective therapies for MDS is a major factor that is expected to drive growth of the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market over the forecast period. Moreover, increasing knowledge regarding the disease and its symptoms with advanced methods and techniques for early diagnosis and treatment for various forms of the MDS are supporting the market growth. Key pharmaceutical organizations in the U.S, Europe, and China myelodysplastic syndrome (MDS) treatment market such as Celgene are focusing on research and development (R&D) of MDS specific drugs and several of their drugs are showing potential in the clinical trials. For instance, in July 2018, Celgene (a part of Bristol Myers Squibb) and Acceleron collaborated and announced that luspatercept which is a medication used in the management and treatment of anemia in myelodysplastic syndromes, achieved all primary and key secondary endpoints in the phase III MEDALIST and BELIEVE trials in patients with low-to-intermediate risk myelodysplastic syndrome (MDS) and transfusion-dependent beta thalassemia, respectively.

request-sample

U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 2,042.6 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 7.6% 2027 Value Projection: US$ 3,404.1 Mn
Geographies covered:
  • U.S., Europe (U.K., Germany, Italy, France, Spain, Russia, Rest of Europe), and China
Segments covered:
  • By Drugs: Lenalidomide, Decitabine, Azacitidine, Luspatercept, Phase 3 Drugs
  • By Route of Administration: Injection, OralOthers
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Bristol Myers Squibb, Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Acceleron Pharma, Inc., Onconova Therapeutics, Inc., Aprea Therapeutics, Geron, Fibrogen, Inc., Jazz Pharmaceuticals, AbbVie Inc., Lixte Biotechnology Holdings, Inc., Gilead Sciences, CrystalGenomics, Inc., ALX Oncology Inc., and Keros Therapeutics.

Growth Drivers:
  • Growing effort to introduce highly effective therapies for various MDS types
  • Rising implications like aging population diagnosed with myelodysplastic syndrome (MDS)
Restraints & Challenges:
  • Complexity of hematopoietic dysfunction in myelodysplastic syndrome (MDS)

Figure 2. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market Share (%), by Drugs, 2020

U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment  | Coherent Market Insights

U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency. Moreover, coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products, and affected growth of the Myelodysplastic Syndrome (MDS) treatment businesses of various companies across the U.S, Europe, and China, as COVID 19 pandemic has led to unprecedented lockdown in several countries, globally. This lockdown has resulted in the closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of the products. Thus, COVID-19 pandemic has affected the economy by directly affecting the production and demand, by creating disruptions in distribution channels and also by its financial impact on firms and financial markets. For instance, according to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in over 100 million infected individuals worldwide and 25.6 million individuals in the U.S., 89,272 individuals in the China as of January 28, 2021. Thus, the impact of coronavirus (COVID-19) pandemic is expected to limit growth of the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market during the forecast period.

U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market: Restraint

Increased complexity of MDS disease may lead to death due to infection caused from low blood cell counts or after the disease becomes acute myeloid leukemia (AML). About a third of patients with MDS develop AML. This generates major hurdle in the development of effective MDS treatment. MDS represents several different conditions, as it is not just a single disease, but it is grouped together by several clinical characteristics. For instance, according to the data published in the Hematology journal of American Society of Hematology Education Program in December 2017, the type and complexity of hematopoietic dysfunction in MDS are highly variable and the kinetics of disease progression are difficult to predict. Moreover, genetic characteristics of MDS are powerfully associated with clinical phenotype. An enhanced understanding of the regulatory logic of MDS genetics may stimulate refined and biologically based diagnostic and monitoring schemes that may be integrated into clinical practice.

Key Players

Major players operating in the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market include Bristol Myers Squibb, Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Acceleron Pharma, Inc., Onconova Therapeutics, Inc., Aprea Therapeutics, Geron, Fibrogen, Inc., Jazz Pharmaceuticals, AbbVie Inc., Lixte Biotechnology Holdings, Inc., Gilead Sciences, CrystalGenomics, Inc., ALX Oncology Inc., and Keros Therapeutics.

In myelodysplastic syndrome (MDS), some of the blood forming cells in bone marrow become abnormal and have problems in forming new and mature blood cells. The immature blood cells called as blasts get stored in the bone marrow and blood, and obstruct the natural function of the hematological system, which results in depletion of healthy red blood cells, platelets, and white blood cells. It is usually observed in geriatric population and more often in older men compared to women. For instance, according to the American Society of Clinical Oncology (ASCO), age plays an important role in the occurrence of myelodysplastic syndrome, as most of the people diagnosed with the disease are of age 65 and older. 

Moreover, increasing possibility of MDS to further progress into rapidly growing cancer of bone marrow cells called acute myeloid leukemia (AML), leads to increasing efforts by key players develop highly effective therapies for MDS treatment. Furthermore, rising awareness about MDS and its symptoms with advanced methods and techniques for early diagnosis and treatment for various forms of the MDS is expected to drive the market growth over the forecast period. Increased understanding of the pathology of the syndrome is directing the research towards developing more specialized and symptom based treatments with effective costs, so that MDS patients can avail these benefits.

Market Dynamics

The increasing prevalence of MDS is expected to drive the demand of drugs used for the treatment of MDS, thereby expected to drive the U.S., Europe, and China myelodysplastic syndrome treatment market growth over the forecast period. Incidence rate for myelodysplastic syndrome has witnessed an increase in the last few years as the average population is ageing every consecutive year. For instance, according to the American Cancer Society report 2018, over 10,000 new cases of MDS occur in the U.S. every year, which is expected to boost the market growth.

Key features of the study:

  • This report provides in-depth analysis of the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and Strategies
  • Key companies covered as a part of this study include Bristol Myers Squibb, Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Acceleron Pharma, Inc., Onconova Therapeutics, Inc., Aprea Therapeutics, Geron, Fibrogen, Inc., Jazz Pharmaceuticals, AbbVie Inc., Lixte Biotechnology Holdings, Inc., Gilead Sciences, CrystalGenomics, Inc., ALX Oncology Inc., and Keros Therapeutics.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market

Detailed Segmentation:

  • U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Drugs:
    • Lenalidomide
    • Decitabine
    • Azacitidine
    • Luspatercept
    • Phase 3 Drugs
  • U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Route of Administration:
    • Injection
    • Oral
  • U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Country/Region:
    • U.S.
      • By Drugs
        • Lenalidomide
        • Decitabine
        • Azacitidine
        • Luspatercept
        • Phase 3 Drugs
      • By Route of Administration
        • Injection
        • Oral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Drugs
        • Lenalidomide
        • Decitabine
        • Azacitidine
        • Luspatercept
        • Phase 3 Drugs
      • By Route of Administration
        • Injection
        • Oral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • U.K.
      • By Drugs
        • Lenalidomide
        • Decitabine
        • Azacitidine
        • Luspatercept
        • Phase 3 Drugs
      • By Route of Administration
        • Injection
        • Oral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Germany
      • By Drugs
        • Lenalidomide
        • Decitabine
        • Azacitidine
        • Luspatercept
        • Phase 3 Drugs
      • By Route of Administration
        • Injection
        • Oral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Italy
      • By Drugs
        • Lenalidomide
        • Decitabine
        • Azacitidine
        • Luspatercept
        • Phase 3 Drugs
      • By Route of Administration
        • Injection
        • Oral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • France
      • By Drugs
        • Lenalidomide
        • Decitabine
        • Azacitidine
        • Luspatercept
        • Phase 3 Drugs
      • By Route of Administration
        • Injection
        • Oral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Spain
      • By Drugs
        • Lenalidomide
        • Decitabine
        • Azacitidine
        • Luspatercept
        • Phase 3 Drugs
      • By Route of Administration
        • Injection
        • Oral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Russia
      • By Drugs
        • Lenalidomide
        • Decitabine
        • Azacitidine
        • Luspatercept
        • Phase 3 Drugs
      • By Route of Administration
        • Injection
        • Oral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Rest of Europe
      • By Drugs
        • Lenalidomide
        • Decitabine
        • Azacitidine
        • Luspatercept
        • Phase 3 Drugs
      • By Route of Administration
        • Injection
        • Oral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • China
      • By Drugs
        • Lenalidomide
        • Decitabine
        • Azacitidine
        • Luspatercept
        • Phase 3 Drugs
      • By Route of Administration
        • Injection
        • Oral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Bristol Myers Squibb*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Otsuka Pharmaceutical Co., Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Limited
    • Cipla Limited
    • Acceleron Pharma, Inc.
    • Onconova Therapeutics, Inc.
    • Aprea Therapeutics
    • Geron
    • Fibrogen, Inc.
    • Jazz Pharmaceuticals
    • AbbVie Inc.
    • Lixte Biotechnology Holdings, Inc.
    • Gilead Sciences
    • CrystalGenomics, Inc.
    • ALX Oncology Inc.
    • Keros Therapeutics.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drugs
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
      • Market Opportunity Map
  3. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market Dynamics
    • Drivers
    • Restraints
    • Opportunity
    • Impact Analysis
    • Pipeline Analysis
    • Regulatory Scenario
    • Market Trends
    • Product Launch
    • PEST Analysis
    • Key Developments
    • Collaborations & Acquisitions
    • Epidemiology
    • Brand Analysis
  4. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market - Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • COVID-19 Epidemiology
    • Supply Chain Analysis
    • Government Initiatives
  5. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Drugs, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
    • Introduction
      • Market Share Analysis, 2020 and 2027(%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Lenalidomide
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
    • Decitabine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
    • Azacitidine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
    • Luspatercept
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
    • Phase 3 Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
  6. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Route of Administration, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
    • Introduction
      • Market Share Analysis, 2020 and 2027(%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Injection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million
  7. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Distribution Channel, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
    • Introduction
      • Market Share Analysis, 2020 and 2027(%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Country at Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (Value in US$ Mn) and (Volume in Units)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (Value in US$ Mn) and (Volume in Units)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (Value in US$ Mn) and (Volume in Units)
  8. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Country/Region, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
    • Introduction
      • Market Share Analysis, 2020 and 2027(%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Country/Regional Trends
    • U.S.
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
        • U.K.
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
        • Germany
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
        • Italy
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
        • France
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
        • Spain
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
        • Russia
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
        • Rest of Europe
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
    • China
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
  9. Company Profiles
    • Bristol Myers Squibb
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Otsuka Pharmaceutical Co., Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Teva Pharmaceutical Industries Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Mylan N.V.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Reddy's Laboratories Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Sun Pharmaceutical Industries Limited
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Cipla Limited
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Acceleron Pharma, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Onconova Therapeutics, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Aprea Therapeutics
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Geron
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Fibrogen, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Jazz Pharmaceuticals
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • AbbVie Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Lixte Biotechnology Holdings, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Gilead Sciences
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • CrystalGenomics, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • ALX Oncology Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Keros Therapeutics
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
  10. Section
    • Research Methodology
    • About us

*Browse 77 market data tables and 41 figures on "myelodysplastic syndrome (MDS) treatment market” - U.S., Europe, and China forecast to 2027

FAQgrowicon

Frequently Asked Questions

The U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market size is estimated to be valued at US$ 2,042.6 Million in 2020 and is expected to exhibit a CAGR of 7.6% between 2020 and 2027.
The growing effort to introduce highly effective therapies for various MDS types and rising implications like aging population diagnosed with myelodysplastic syndrome (MDS) are expected to drive the market growth over the forecast period.
Injection is expected to be the leading route of administration segment in the market.
Complexity of hematopoietic dysfunction in myelodysplastic syndrome (MDS) is the major factor that is expected to restrain growth of the market.
Major players operating in the market include Bristol Myers Squibb, Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Acceleron Pharma, Inc., Onconova Therapeutics, Inc., Aprea Therapeutics, Geron, Fibrogen, Inc., Jazz Pharmaceuticals, AbbVie Inc., Lixte Biotechnology Holdings, Inc., Gilead Sciences, CrystalGenomics, Inc., ALX Oncology Inc., and Keros Therapeutics.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.